Karyopharm Therapeutics Inc (KPTI) Expected to Post FY2022 Earnings of $2.60 Per Share

Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Investment analysts at Wedbush issued their FY2022 earnings estimates for Karyopharm Therapeutics in a research note issued to investors on Thursday. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of $2.60 for the year.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. started coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They issued a “buy” rating and a $23.00 target price for the company. BidaskClub raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Royal Bank of Canada reaffirmed a “buy” rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $17.33.

Shares of Karyopharm Therapeutics (KPTI) traded down $0.63 during midday trading on Monday, hitting $11.80. 147,038 shares of the company’s stock were exchanged, compared to its average volume of 191,150. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%.

In related news, SVP Christopher Brett Primiano sold 27,042 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total transaction of $277,991.76. Following the completion of the sale, the senior vice president now directly owns 11,381 shares of the company’s stock, valued at $116,996.68. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $10.39, for a total transaction of $103,900.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,000 shares of company stock valued at $730,969. 14.71% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics during the second quarter worth approximately $136,000. Voya Investment Management LLC raised its stake in shares of Karyopharm Therapeutics by 42.1% during the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Karyopharm Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after purchasing an additional 5,586 shares during the period. ProShare Advisors LLC grew its holdings in Karyopharm Therapeutics by 8.0% during the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Karyopharm Therapeutics by 33.6% during the second quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock valued at $255,000 after purchasing an additional 7,099 shares during the period. 60.92% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Karyopharm Therapeutics Inc (KPTI) Expected to Post FY2022 Earnings of $2.60 Per Share” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/01/30/karyopharm-therapeutics-inc-kpti-expected-to-post-fy2022-earnings-of-2-60-per-share.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History and Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit